OncoMatch/Clinical Trials/NCT06463028
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Is NCT06463028 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Sapanisertib and Serabelisib for endometrial cancer.
Treatment: Sapanisertib · Serabelisib · Paclitaxel — This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: checkpoint inhibitor
Lab requirements
Cardiac function
Significant cardiovascular impairment; Prolongation of QTc interval to >480 ms
Significant cardiovascular impairment. Prolongation of QTc interval to >480 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- University of California, San Francisco (UCSF) · San Francisco, California
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- Florida Cancer Specialists, North · St. Petersburg, Florida
- Florida Cancer Specialists, East · West Palm Beach, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06463028 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and checkpoint inhibitor.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages